CIPROKANT-500 (Ciprofloxacin)

DIOCIPRO® TABLETS (Ciprofloxacin 500mg USP)

Ciprofloxacin 500mg USP

DIOCIPRO® is indicated for Urinary tract infections caused by Escherichia coli, Klebsiella Pneume, Enterobacter Cloacae, Serratia Marcescens, Proteus Mirabilis, Pseudomonas Auriginosa and Staphylococcus Saprophyyticus.

DIOCIPRO® is indicated also for Acute uncomplicated cystitis in females caused by Escherichia coli or staphy, Chronic Prostatitis caused by Escherichia coli or Proteus Mirabilis, also used to treat Lower respiratory tract infections, infectious diarrhea, typhoid fever as well as uncomplicated cervical urethral gonorrhea.

Advertisement

Dosage and directions for use

Adults: DIOCIPRO® usually given by mouth in a dose of 250-750mg twice daily for 5 to 14 days or more depending on the type of infection.

Children: since DIOCIPRO® can cause degenerative in weight bearing joints of young animals, they should only be used in children and adolescents where their use may justified if the benefits outweigh the risks. 10mg/kg to 20mg/kg (maximum 750mg per dose: not be exceeded even in patients weighing >51kg).

Contraindications

DIOCIPRO® is contraindicated to patients who are hypersensitive to ciprofloxacin.

Side effects and adverse reactions

Gastrointestinal disturbances include nausea, vomiting, diarrhea, abdominal pain dyspepsia are frequent adverse effects. Headache, dizziness and restlessness are among the commonest effects on the CNS.

Drug interaction

The range of drug interactions reported with ciprofloxacin and other fluoroquinolones continues to grow.  Fluoroquinolones are known to inhibit drug metabolism and may interfere with the clearance of drugs metabolized by the liver such as theophylline. On the other hand, cations like Aluminium, Magnesium or iron reduce the absorption of ciprofloxacin and related drugs when given concomitantly.

Advertisement
 Precautions and warnings

Ciprofloxacin should be used with caution in patients with epilepsy or history of CNS disorders. Care is necessary in patients with impaired hepatic or renal function, glucose 6-phosphate dehydrogenase deficiency or myasthenia gravis.

Advertisement

Leave a Reply

%d bloggers like this: